News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Announces Plans To Make PROVENGE® Commercially Available In Europe


3/3/2014 8:17:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Dendreon Corporation today announced that it plans to make PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES